Celcuity(NASDAQ) CELC

Celcuity Inc. makes new medicines to treat different types of cancer. These drugs help doctors target specific tumors in adult patients. The company focuses on improving how well cancer treatments work.

Targeted Therapies and Testing

• REVTORPYK: Targeted treatment for adult patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative advanced breast cancer; accounts for 0% of revenue as of June 30, 2026.
• Gedatolisib Pipeline: Clinical programs evaluating treatments for metastatic prostate and endometrial cancers; currently generates no revenue.
• CELx Platform: Diagnostic technology designed to identify specific abnormal cellular processes in living tumor cells using the company's proprietary platform.

Major Milestones and Clinical Steps

• Licensed the exclusive global rights for the drug gedatolisib from Pfizer in April 2021.
• Received FDA approval for REVTORPYK to treat patients with advanced breast cancer in July 2026.
• Completed the issuance of $575.0 million in convertible notes in June 2026 to fund operations.
• Opened an Expanded Access Program in August 2026 to provide medication to patients before its commercial launch.
• Initiated a Phase 1b/2 clinical trial for the treatment of metastatic castration-resistant prostate cancer in February 2024.

A New Way to Block Growth

Celcuity uses a specialized approach to block the PI3K/AKT/mTOR signaling pathway, which regulates cell survival and tumor growth. By blocking four types of PI3K enzymes and two mTOR complexes at once, the treatment aims to prevent cancer cells from becoming resistant to therapy.

Tracking the Financial Path

• Market capitalization was $5.7 billion as of the quarter ended June 30, 2026, up 880.7% year over year.
• Net loss was $78.9 million for the three-month period ended June 30, 2026, up 74% year over year.
• Selling, general, and administrative expenses reached $35.0 million in the quarter ended June 30, 2026, up 361% year over year.
• Total cash, cash equivalents, and short-term investments reached $754.0 million as of June 30, 2026.
• Accumulated deficit reached $580.6 million as of June 30, 2026, due to ongoing research and development costs.

Bottom Line

Celcuity has transitioned from identifying cancer sub-types to commercializing its first FDA-approved treatment. Its focus on the PI3K and mTOR pathways provides a specialized foundation for growth in the oncology market.